AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers
Advanced Search

Session Details

Corporate Exhibits

[3F]Corporate Exhibits

Mon. Mar 17, 2025 6:00 PM - 8:50 PM JST
Mon. Mar 17, 2025 9:00 AM - 11:50 AM UTC
Entrance (3F)

[3F-01T]Immunogenicity in mice after percutaneous vaccination with HA microneedle array patch vaccine

Masaki Ishibashi1, *Junichi Hinagata1, Hidetoshi Hamamoto1 (1. MedRx Co., Ltd. (Japan))
Comment()

[3F-02T]Formulation Development of Intranazsal Vaccine and design of spray device for Intranasal Vaccine

Takayuki Nakamura1, *Yuki Katagiri1, Yasuyuki Shiraishi1, Takashi Kamishita2, Toshiaki Takagi2, Natsumi Kodake2, Takashi Miyazaki2 (1. TaiseiKako Co,.Ltd (Japan), 2. TOKO YAKUHINKOGYO CO.,LTD. (Japan))
Comment()

[3F-03T]The strategy to achieve high efficacy and safety in mRNA therapeutics

*Tetsuo Yoshida1,2, Rena Akahori2,3, Akiko Yanagiya2, Naoki Matsumoto2, Daichi Matsuura2, Hayato Sato2, Hiroaki Murakami2, Tomohiro Sawadaishi2, Yanwen Feng2, Jun Nihira2, Satoshi Abe2, Kazuyuki Nakashima2 (1. Axcelead, Inc. (Japan), 2. ARCALIS, Inc. (Japan), 3. Hitachi, Ltd. (Japan))
Comment()

[3F-04T]Sysmex Company Profile and Initiatives Focused on Regenerative Medicine

*Takuya Hasegawa1, Hideyuki Kawamoto1, Taro Iwasa1 (1. Sysmex Corp. (Japan))
Comment()

[3F-05T]Autonomous Optimization of Vaccine Development Processes: from Patient Administration Schedule to Manufacturing Efficiency.

*Taku Tsuzuki1, Tsuyoshi Tatsukawa1, Yosuke Ozawa2 (1. Epistra Inc. / cSIMVa Chiba University (Japan), 2. Epistra Inc. (Japan))
Comment()

[3F-06]Development of new vaccine adjuvant based on self-assembling peptide technology.

*Satoru Kobayashi1, Noriaki Matsuda1 (1. 3-D Matrix, Ltd (Japan))
Comment()

[3F-07]Vaccine Business in Daiichi Sankyo

*Hideki Ishiwata1, Takashi Mochizuki1 (1. Daiichi Sankyo Co., Ltd. Vaccine Business Department (Japan))
Comment()

[3F-08]Company Introduction

*Akihito Sawada1, Yusuke Okada1, Takeru Yamakawa1 (1. Infectious Disease Control Labs, Group 1 Drug Discovery Department Meiji Seika Pharma Co., Ltd. (Japan))
Comment()

[3F-09]Development of a universal flavivirus vaccine: Immunoinformatics-driven identification of conserved epitopes for B6 mouse alleles

*Po-hung Wang1, Shuhei Taguwa2, Kazuo Yamashita1 (1. KOTAI Biotechnologies, Inc. (Japan), 2. Osaka University (Japan))
Comment()

[3F-10]SNBL's Platform Technology of Nasal Drug Delivery System for Mucosal Vaccine

*Ryota Ise1, Yo Sonoda1 (1. SNBL, Ltd. (Japan))
Comment()

[3F-11]Hight performance innovative nasal spray device.

*Yuichi Yoshimura1 (1. Nipro Corporation (Japan))
Comment()

[3F-12]KM Biologics Co., Ltd.

*Masafumi Endo1, Yasuhiko Shinmura1 (1. KM Biologics Co., Ltd. (Japan))
Comment()

[3F-13]What is about Nobelpharm.Co.Ltd ?

*Yoko Yoshimura1, Kentaro Kasama1, Masayoshi Imada1, Yoshinao Kobayashi1 (1. Nobelpharma Co., Ltd. (Japan))
Comment()

[3F-14]NEC's cutting-edge AI and ICT technologies in combating infectious diseases

*Kazuhide Onoguchi1 (1. NEC Corporation (Japan))
Comment()

[3F-15]Cytiva's solution in vaccine manufacturing

masahiro oda1, *PeiQing Zhang1 (1. Global Life Science Technologies Japan (Cytiva) (Japan))
Comment()
Back to Category List